Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

916 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Clinical, pathological and genetic features of follicular lymphoma grade 3A: a joint analysis of the German low-grade and high-grade lymphoma study groups GLSG and DSHNHL.
Koch K, Hoster E, Ziepert M, Unterhalt M, Ott G, Rosenwald A, Hansmann ML, Bernd W, Stein H, Pöschel V, Dreyling M, Trümper L, Löffler M, Schmitz N, Hiddemann W, Pfreundschuh M, Klapper W. Koch K, et al. Among authors: hiddemann w. Ann Oncol. 2016 Jul;27(7):1323-9. doi: 10.1093/annonc/mdw185. Epub 2016 Apr 26. Ann Oncol. 2016. PMID: 27117536 Free article.
Tumor sclerosis but not cell proliferation or malignancy grade is a prognostic marker in advanced-stage follicular lymphoma: the German Low Grade Lymphoma Study Group.
Klapper W, Hoster E, Rölver L, Schrader C, Janssen D, Tiemann M, Bernd HW, Determann O, Hansmann ML, Möller P, Feller A, Stein H, Wacker HH, Dreyling M, Unterhalt M, Hiddemann W, Ott G; German Low Grade Lymphoma Study Group. Klapper W, et al. Among authors: hiddemann w. J Clin Oncol. 2007 Aug 1;25(22):3330-6. doi: 10.1200/JCO.2006.10.5833. J Clin Oncol. 2007. PMID: 17664481
Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registry.
Pastore A, Jurinovic V, Kridel R, Hoster E, Staiger AM, Szczepanowski M, Pott C, Kopp N, Murakami M, Horn H, Leich E, Moccia AA, Mottok A, Sunkavalli A, Van Hummelen P, Ducar M, Ennishi D, Shulha HP, Hother C, Connors JM, Sehn LH, Dreyling M, Neuberg D, Möller P, Feller AC, Hansmann ML, Stein H, Rosenwald A, Ott G, Klapper W, Unterhalt M, Hiddemann W, Gascoyne RD, Weinstock DM, Weigert O. Pastore A, et al. Among authors: hiddemann w. Lancet Oncol. 2015 Sep;16(9):1111-1122. doi: 10.1016/S1470-2045(15)00169-2. Epub 2015 Aug 6. Lancet Oncol. 2015. PMID: 26256760
Current treatment strategies in follicular lymphomas.
Hiddemann W, Unterhalt M. Hiddemann W, et al. Ann Oncol. 2006 Sep;17 Suppl 10:x155-9. doi: 10.1093/annonc/mdl253. Ann Oncol. 2006. PMID: 17018716 Free article. Review. No abstract available.
Initial chemotherapy with mitoxantrone, chlorambucil, prednisone impairs the collection of stem cells in patients with indolent lymphomas--results of a randomized comparison by the German Low-Grade Lymphoma Study Group.
Nickenig C, Dreyling M, Hoster E, Ludwig WD, Dörken B, Freund M, Huber C, Ganser A, Trümper L, Forstpointner R, Unterhalt M, Hiddemann W. Nickenig C, et al. Among authors: hiddemann w. Ann Oncol. 2007 Jan;18(1):136-142. doi: 10.1093/annonc/mdl348. Epub 2006 Oct 27. Ann Oncol. 2007. PMID: 17071931 Free article. Clinical Trial.
Similar clinical features in follicular lymphomas with and without breaks in the BCL2 locus.
Leich E, Hoster E, Wartenberg M, Unterhalt M, Siebert R, Koch K, Klapper W, Engelhard M, Puppe B, Horn H, Staiger AM, Stuhlmann-Laeisz C, Bernd HW, Feller AC, Hummel M, Lenze D, Stein H, Hartmann S, Hansmann ML, Möller P, Hiddemann W, Dreyling M, Ott G, Rosenwald A; German Low Grade Lymphoma Study Group (GLSG). Leich E, et al. Among authors: hiddemann w. Leukemia. 2016 Apr;30(4):854-60. doi: 10.1038/leu.2015.330. Epub 2015 Dec 1. Leukemia. 2016. PMID: 26621338
Moderate increase of secondary hematologic malignancies after myeloablative radiochemotherapy and autologous stem-cell transplantation in patients with indolent lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group.
Lenz G, Dreyling M, Schiegnitz E, Haferlach T, Hasford J, Unterhalt M, Hiddemann W. Lenz G, et al. Among authors: hiddemann w. J Clin Oncol. 2004 Dec 15;22(24):4926-33. doi: 10.1200/JCO.2004.06.016. J Clin Oncol. 2004. PMID: 15611507 Clinical Trial.
916 results